ADL5747: Phase IIa started

In January, Adolor and Pfizer began a double-blind, placebo-controlled, crossover Phase IIa trial to compare 150 mg ADL5747 given twice daily vs. Lyrica pregablin for 2 weeks in 92 patients. Pfizer, ...